CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it has retained the services of Skyline Corporate Communications Group, LLC (“Skyline”) to manage its investor relations and corporate communications activities within the financial community.
Skyline Corporate Communications Group, LLC, with offices in Boston and New York City, is an investor relations and corporate communications firm that provides strategic messaging and investor communications consulting services for public corporations. Skyline provides strategic assistance for companies in the financial markets and investment community by assisting them to effectively communicate their corporate message and competitive advantages.
Jay Roberts, Vyant Bio’s Chief Executive Officer, stated: “Our recent scientific activities, clinical achievements, and upcoming clinical milestones prompted Vyant Bio to select Skyline as our investor relations firm. Vyant Bio is developing and bringing important therapeutic assets into our pipeline that we expect to enhance shareholder value. Vyant Bio believes that Skyline’s strong…
